SBC Medical Group Holdings (Nasdaq: SBC) reported fiscal Q2 2026 revenue of $49.2 million, up 13% year over year, while basic and diluted EPS rose to $0.10 from $0.02. Net income attributable to SBC Medical increased 335% to $10.7 million, supported by wider operating margins, lower tax expense, service-fee increases, and growth in the points business.

Core earnings data

Revenue growth translated into stronger operating leverage. Cost of revenue was nearly unchanged despite the 13% increase in sales, lifting gross margin by approximately 3.9 percentage points, while operating income grew about 30% even as selling, general and administrative expenses increased 10%.

Adjusted EBITDA, a non-GAAP measure, rose faster than revenue and reached a 41% margin. Below the operating line, a foreign-exchange gain and lower income tax expense further amplified net income growth.

Margin calculations labeled “approximately” are based on the reported revenue and profit figures. Adjusted EBITDA and its margin are non-GAAP measures.

Business and operating performance

Revenue from related parties increased approximately 12% to $43.7 million, while other revenue grew approximately 24% to $5.5 million. Related-party revenue therefore remained the dominant source of consolidated sales, accounting for roughly 89% of the quarter’s total.

SBC Medical attributed the earnings acceleration to expansion of its points business following an operating-policy change and higher service fees linked to enhanced AI-enabled support. The company identified AI-powered call centers, marketing, and clinic-site selection as areas where its support platform is being expanded.

Operating activity across the supported clinic network also increased. Locations reached 287 at the end of June, up 34 from a year earlier. Patient visits for the 12 months ended June 30 rose 10% to 6.9 million, while average spending per visit increased 9% to $287. These figures cover the supported and partnership network rather than only SBC Medical’s consolidated operations.

Profitability, cash flow, and the balance sheet

Operating income increased about 30%, but below-the-line items made the rise in net income considerably larger. SBC Medical recorded a $1.0 million foreign-exchange gain, compared with a $0.8 million loss a year earlier, creating an approximately $1.8 million favorable swing. Income tax expense also fell to $7.8 million from $11.1 million even as pretax income rose to $19.6 million from $13.5 million.

Cash-flow information was provided only for the first half, not for Q2 separately. First-half operating cash flow improved to $31.7 million from a $6.4 million outflow. Working-capital movements contributed materially, including an $11.2 million cash-flow contribution from income taxes payable and $6.6 million from accounts payable, partly offset by a $14.6 million use of cash from related-party accounts receivable.

Cash and cash equivalents increased to $184.3 million at June 30 from $163.8 million at the end of 2025. Current and non-current bank and other borrowings totaled approximately $37.8 million, down from $42.8 million. However, related-party accounts receivable rose to $40.7 million from $27.5 million, increasing the amount of capital tied to affiliated counterparties.

Q2 reacceleration has not yet erased first-half pressure

The strong quarterly growth contrasts with more subdued first-half results. Revenue for the first six months increased 2% to $92.2 million, but net income attributable to SBC Medical declined 8% to $22.0 million, and adjusted EBITDA fell 4% to $38 million.

One factor affecting the comparison was an $8.7 million gain from the redemption of life insurance policies recorded in the first half of 2025, with no corresponding gain in 2026. The first-half figures therefore show that Q2 improved the company’s recent trajectory, but the acceleration will need to persist before it is fully reflected in year-to-date earnings growth.

Management priorities and fee revisions

Management said structural reforms undertaken in 2025 had been completed and identified clinic expansion, average fees per clinic, and a broader service menu as the platform’s principal growth drivers. It expects revised call-center fees for five affiliated medical corporations, together with separate fee changes for Rize Clinic and Gorilla Clinic, to add approximately $15 million to annual service fees if the initiatives’ full-year impact is realized. This estimate was converted at ¥158.1 per U.S. dollar and is not a comprehensive company-wide financial forecast.

SBC Medical also plans to expand its domestic multi-brand aesthetic dermatology strategy and non-aesthetic services. International priorities include its OrangeTwist collaboration in the United States, expansion in Southeast Asia centered on Thailand, and preparations to enter the longevity market.

Recent insider transactions

The supplied insider dataset lists seven transactions over the past two years, including three sales by Chairman and CEO Yoshiyuki Aikawa in March and April 2026 with a combined reported value of approximately $27.2 million. A separate summary in the same dataset states that there were no transactions during the latest six months, which conflicts with the dated records below and should be checked against the underlying regulatory filings.

The reported transactions do not, by themselves, establish the insiders’ views about SBC Medical’s valuation or future performance.

Risks investors need to watch

• Q2 momentum may not persist: First-half net income and adjusted EBITDA remained below their prior-year levels despite the quarterly acceleration.
• Related-party concentration: Approximately 89% of Q2 revenue came from related parties, while related-party accounts receivable increased substantially from year-end.
• Fee-revision benefits are conditional: The estimated $15 million annual contribution assumes the initiatives achieve a full year of impact and is concentrated among a limited group of affiliated medical corporations and clinic brands.
• Below-the-line volatility: Q2 profit benefited from a favorable foreign-exchange swing and lower tax expense. Currency translation reduced first-half comprehensive income and exchange-rate changes reduced cash by $7.4 million.

Summary

SBC Medical’s fiscal Q2 2026 showed a clear improvement in revenue growth and operating profitability, with nearly flat cost of revenue supporting wider margins and fee revisions contributing to the acceleration. Lower taxes and a favorable currency swing further increased net income, while first-half operating cash flow turned positive and the cash balance grew. The main points to monitor are whether Q2 growth can lift full-year earnings trends, whether the expected fee benefits are realized, and how the company manages its high related-party exposure while expanding its clinic network and international operations.

Find out more